Search

Displaying results 2391 - 2400 of 10000 in total
  1. Drug

    MF101

    go.drugbank.com/drugs/DB05052
    Investigational

    MF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone therapies, does not activate the estrogen receptor alpha (ERα), known to be implicated in tumor formation … MF101 is an oral drug designed for the treatment of hot flashes and night sweats in peri-menopausal and menopausal women.

  2. Drug

    Abrocitinib

    go.drugbank.com/drugs/DB14973
    ApprovedInvestigational

    [L39774] The Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signalling pathway plays a central role in the pathogenesis of a variety of autoimmune and inflammatory diseases, … [L39784] On January 14, 2022, the FDA approved abrocitinib for the treatment of refractory, moderate-to-severe AD in adults whose disease is not adequately controlled with other systemic drug products,

  3. Drug

    Aprocitentan

    go.drugbank.com/drugs/DB15059
    ApprovedInvestigational

    [L50261] It was the first antihypertensive employing a novel mechanism to be approved in almost 40 years.[L50261] … Aprocitentan is a dual antagonist of endothelin receptors A and B used for treatment-resistant hypertension. It is the active metabolite of [macitentan].

  4. Drug

    ATG-Fresenius S

    go.drugbank.com/drugs/DB05320
    Investigational

    ATG-Fresenius S is a concentrated anti-human T-lymphocyte immunoglobulin preparation derived from rabbits after immunization with a T-lympoblast cell line. … ATG-Fresenius S is an immunosuppressive product for the prevention and treatment of acute rejection following organ transplantation.

  5. Drug

    Glucagon

    go.drugbank.com/drugs/DB00040
    ApprovedInvestigational

    Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia. … [L7640,L7643] Glucagon was granted FDA approval on 14 November 1960.[L7631]

    Categories: Decreased GI Motility, Decreased GI Smooth Muscle Tone
  6. Drug

    Macitentan

    go.drugbank.com/drugs/DB08932
    ApprovedInvestigational

    Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension (PAH).[L35890] It was first approved by the FDA in 2013. … A combination product (Opsynvi) comprising macitentan and [tadalafil] was approved in Canada in October 2021 for the treatment of PAH.[L39105] It was subsequently approved by the FDA in March 2024.

    Categories: Endothelin A Receptor Antagonists
  7. Drug

    Bromotheophylline

    go.drugbank.com/drugs/DB14018
    Approved

    [L1082] It is also approved by Health Canada to be used alone or in combination with [DB00316] in OTC products.[L1113] … [A33018] Bromotheophylline is categorized on the FDA as a drug substance with an inactive state since March, 1980.

  8. Drug

    Natalizumab

    go.drugbank.com/drugs/DB00108
    ApprovedInvestigational

    Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. … In 2006, the FDA reintroduced the drug to the market for multiple sclerosis.[A261326] Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008.

  9. Drug

    Imgatuzumab

    go.drugbank.com/drugs/DB14884
    Investigational

    Imgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With

  10. Drug

    Amphetamine

    go.drugbank.com/drugs/DB00182
    ApprovedIllicitInvestigational

    [L5194] During World War II, amphetamine was used to promote wakefulness in the soldiers. … It was previously used for a large variety of conditions and this changed until this point where its use is highly restricted.

    Mixtures: Mixed Salts of a Single-Entity Amphetamine Product, Mixed Salts of a Single-Entity Amphetamine Product